{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:48:45Z","timestamp":1770752925516,"version":"3.50.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The survival of glioma patients with the current treatments is poor. Early clinical trails with replicating adenoviruses demonstrated the feasibility and safety of the use of adenoviruses as oncolytic agents. Antitumor efficacy has been moderate due to inefficient virus replication and spread. Previous studies have shown that truncation of the adenovirus i-leader open reading frame enhanced cytopathic activity of HAdV-5 in several tumor cell lines. Here we report the effect of an i-leader mutation on the cytopathic activity in glioma cell lines and in primary high-grade glioma cell cultures.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A mutation truncating the i-leader open reading frame was created in a molecular clone of replication-competent wild-type HAdV-5 by site-directed mutagenesis. We analyzed the cytopathic activity of this RL-07 mutant virus. A cell-viability assay showed increased cytopathic activity of the RL-07 mutant virus on U251 and SNB19 glioma cell lines. The plaque sizes of RL-07 on U251 monolayers were seven times larger than those of isogenic control viruses. Similarly, the cytopathic activity of the RL-07 viruses was strongly increased in six primary high-grade glioma cell cultures. In glioma cell lines the RL-07 virus was found to be released earlier into the culture medium. This was not due to enhanced viral protein synthesis, as was evident from equivalent E1A, Fiber and Adenovirus Death Protein amounts, nor to higher virus yields.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The cytopathic activity of replicating adenovirus in glioblastoma cells is increased by truncating the i-leader open reading frame. Such mutations may help enhancing the antitumor cytopathic efficacy of oncolytic adenoviruses in the treatment of glioblastoma.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1743-422x-8-162","type":"journal-article","created":{"date-parts":[[2011,4,12]],"date-time":"2011-04-12T06:21:59Z","timestamp":1302589319000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Truncating the i-leader open reading frame enhances release of human adenovirus type 5 in glioma cells"],"prefix":"10.1186","volume":"8","author":[{"given":"Sanne K","family":"van den Hengel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen","family":"de Vrij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taco G","family":"Uil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine L","family":"Lamfers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter AE","family":"Sillevis Smitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob C","family":"Hoeben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,4,11]]},"reference":[{"key":"1278_CR1","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.ymthe.2004.07.021","volume":"10","author":"EA Chiocca","year":"2004","unstructured":"Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F, et al.: A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 2004, 10: 585-598. 10.1016\/j.ymthe.2004.07.021","journal-title":"Mol Ther"},{"key":"1278_CR2","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/sj.mt.6300403","volume":"16","author":"P Forsyth","year":"2008","unstructured":"Forsyth P, Roldan G, George D, Wallace C, Palmer CA, Morris D, et al.: A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 2008, 16: 627-632. 10.1038\/sj.mt.6300403","journal-title":"Mol Ther"},{"key":"1278_CR3","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/sj.gt.3301205","volume":"7","author":"JM Markert","year":"2000","unstructured":"Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, et al.: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000, 7: 867-874. 10.1038\/sj.gt.3301205","journal-title":"Gene Ther"},{"key":"1278_CR4","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.ymthe.2005.07.357","volume":"12","author":"KJ Pulkkanen","year":"2005","unstructured":"Pulkkanen KJ, Yla-Herttuala S: Gene therapy for malignant glioma: current clinical status. Mol Ther 2005, 12: 585-598. 10.1016\/j.ymthe.2005.07.357","journal-title":"Mol Ther"},{"key":"1278_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/rmv.490","volume":"16","author":"AM Sonabend","year":"2006","unstructured":"Sonabend AM, Ulasov IV, Lesniak MS: Conditionally replicative adenoviral vectors for malignant glioma. Rev Med Virol 2006, 16: 99-115. 10.1002\/rmv.490","journal-title":"Rev Med Virol"},{"key":"1278_CR6","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/sj.cgt.7700928","volume":"13","author":"JN Glasgow","year":"2006","unstructured":"Glasgow JN, Everts M, Curiel DT: Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther 2006, 13: 830-844. 10.1038\/sj.cgt.7700928","journal-title":"Cancer Gene Ther"},{"key":"1278_CR7","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/gt.2008.26","volume":"15","author":"J De Vrij","year":"2008","unstructured":"De Vrij J, Uil TG, van den Hengel SK, Cramer SJ, Koppers-Lalic D, Verweij MC, et al.: Adenovirus targeting to HLA-A1\/MAGE-A1-positive tumor cells by fusing a single-chain T-cell receptor with minor capsid protein IX. Gene Ther 2008, 15: 978-989. 10.1038\/gt.2008.26","journal-title":"Gene Ther"},{"key":"1278_CR8","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1215\/15228517-2007-017","volume":"9","author":"WJ Van Houdt","year":"2007","unstructured":"Van Houdt WJ, Wu H, Glasgow JN, Lamfers ML, Dirven CM, Gillespie GY, et al.: Gene delivery into malignant glioma by infectivity-enhanced adenovirus: in vivo versus in vitro models. Neuro Oncol 2007, 9: 280-290. 10.1215\/15228517-2007-017","journal-title":"Neuro Oncol"},{"key":"1278_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/sj.cgt.7701010","volume":"14","author":"E Brouwer","year":"2007","unstructured":"Brouwer E, Havenga MJ, Ophorst O, de Leeuw B, Gijsbers L, Gillissen G, et al.: Human adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patients. Cancer Gene Ther 2007, 14: 211-219. 10.1038\/sj.cgt.7701010","journal-title":"Cancer Gene Ther"},{"key":"1278_CR10","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1002\/jgm.1385","volume":"11","author":"S Nandi","year":"2009","unstructured":"Nandi S, Ulasov IV, Rolle CE, Han Y, Lesniak MS: A chimeric adenovirus with an Ad 3 fiber knob modification augments glioma virotherapy. J Gene Med 2009, 11: 1005-1011. 10.1002\/jgm.1385","journal-title":"J Gene Med"},{"key":"1278_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/jgm.1008","volume":"9","author":"S Zheng","year":"2007","unstructured":"Zheng S, Ulasov IV, Han Y, Tyler MA, Zhu ZB, Lesniak MS: Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma. J Gene Med 2007, 9: 151-160. 10.1002\/jgm.1008","journal-title":"J Gene Med"},{"key":"1278_CR12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.274.5286.373","volume":"274","author":"JR Bischoff","year":"1996","unstructured":"Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, et al.: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996, 274: 373-376. 10.1126\/science.274.5286.373","journal-title":"Science"},{"key":"1278_CR13","first-page":"437","volume":"76","author":"SJ Edwards","year":"2002","unstructured":"Edwards SJ, Dix BR, Myers CJ, Dobson-Le D, Huschtscha L, Hibma M, et al.: Evidence that Replication of the Antitumor Adenovirus ONYX-015 Is Not Controlled by the p53 and p14ARF Tumor Suppressor Genes. J Virol 2002, 76: 437-445.","journal-title":"J Virol"},{"key":"1278_CR14","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1128\/JVI.80.4.2000-2012.2006","volume":"80","author":"T Subramanian","year":"2006","unstructured":"Subramanian T, Vijayalingam S, Chinnadurai G: Genetic identification of adenovirus type 5 genes that influence viral spread. J Virol 2006, 80: 2000-2012. 10.1128\/JVI.80.4.2000-2012.2006","journal-title":"J Virol"},{"key":"1278_CR15","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1128\/JVI.77.4.2640-2650.2003","volume":"77","author":"W Yan","year":"2003","unstructured":"Yan W, Kitzes G, Dormishian F, Hawkins L, Sampson-Johannes A, Watanabe J, et al.: Developing novel oncolytic adenoviruses through bioselection. J Virol 2003, 77: 2640-2650. 10.1128\/JVI.77.4.2640-2650.2003","journal-title":"J Virol"},{"key":"1278_CR16","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1128\/jvi.57.3.848-856.1986","volume":"57","author":"JS Symington","year":"1986","unstructured":"Symington JS, Lucher LA, Brackmann KH, Virtanen A, Pettersson U, Green M: Biosynthesis of adenovirus type 2 i-leader protein. J Virol 1986, 57: 848-856.","journal-title":"J Virol"},{"key":"1278_CR17","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1128\/jvi.64.2.551-558.1990","volume":"64","author":"PD Soloway","year":"1990","unstructured":"Soloway PD, Shenk T: The adenovirus type 5 i-leader open reading frame functions in cis to reduce the half-life of L1 mRNAs. J Virol 1990, 64: 551-558.","journal-title":"J Virol"},{"key":"1278_CR18","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/jnr.20776","volume":"83","author":"B de Leeuw","year":"2006","unstructured":"de Leeuw B, Su M, ter Horst M, Iwata S, Rodijk M, Hoeben RC, et al.: Increased glia-specific transgene expression with glial fibrillary acidic protein promoters containing multiple enhancer elements. J Neurosci Res 2006, 83: 744-753. 10.1002\/jnr.20776","journal-title":"J Neurosci Res"},{"key":"1278_CR19","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1128\/jvi.70.7.4805-4810.1996","volume":"70","author":"C Chartier","year":"1996","unstructured":"Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, Mehtali M: Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 1996, 70: 4805-4810.","journal-title":"J Virol"},{"key":"1278_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1089\/hum.1996.7.2-215","volume":"7","author":"FJ Fallaux","year":"1996","unstructured":"Fallaux FJ, Kranenburg O, Cramer SJ, Houweling A, Van Ormondt H, Hoeben RC, et al.: Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 1996, 7: 215-222. 10.1089\/hum.1996.7.2-215","journal-title":"Hum Gene Ther"},{"key":"1278_CR21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1006\/abio.1999.4282","volume":"274","author":"P Murakami","year":"1999","unstructured":"Murakami P, McCaman MT: Quantitation of adenovirus DNA and virus particles with the PicoGreen fluorescent Dye. Anal Biochem 1999, 274: 283-288. 10.1006\/abio.1999.4282","journal-title":"Anal Biochem"},{"key":"1278_CR22","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/0042-6822(91)90547-O","volume":"185","author":"JS Hong","year":"1991","unstructured":"Hong JS, Engler JA: The amino terminus of the adenovirus fiber protein encodes the nuclear localization signal. Virology 1991, 185: 758-767. 10.1016\/0042-6822(91)90547-O","journal-title":"Virology"},{"key":"1278_CR23","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1128\/jvi.55.3.533-546.1985","volume":"55","author":"E Harlow","year":"1985","unstructured":"Harlow E, Franza BR, Schley C: Monoclonal antibodies specific for adenovirus early region 1A proteins: extensive heterogeneity in early region 1A products. J Virol 1985, 55: 533-546.","journal-title":"J Virol"},{"key":"1278_CR24","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1128\/jvi.66.6.3633-3642.1992","volume":"66","author":"AE Tollefson","year":"1992","unstructured":"Tollefson AE, Scaria A, Saha SK, Wold WS: The 11,600-MW protein encoded by region E3 of adenovirus is expressed early but is greatly amplified at late stages of infection. J Virol 1992, 66: 3633-3642.","journal-title":"J Virol"},{"key":"1278_CR25","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1128\/jvi.70.4.2296-2306.1996","volume":"70","author":"AE Tollefson","year":"1996","unstructured":"Tollefson AE, Scaria A, Hermiston TW, Ryerse JS, Wold LJ, Wold WS: The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol 1996, 70: 2296-2306.","journal-title":"J Virol"},{"key":"1278_CR26","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/sj.gt.3300695","volume":"5","author":"MJ Driesse","year":"1998","unstructured":"Driesse MJ, Vincent AJPE, Smitt PS, Kros JM, Hoogerbrugge PM, Avezaat CJJ, et al.: Intracerebral injection of adenovirus harboring the HSVtk gene combined with ganciclovir administration: toxicity study in nonhuman primates. Gene Ther 1998, 5: 1122-1129. 10.1038\/sj.gt.3300695","journal-title":"Gene Ther"},{"key":"1278_CR27","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/sj.gt.3301250","volume":"7","author":"MJ Driesse","year":"2000","unstructured":"Driesse MJ, Esandi MC, Kros JM, Avezaat CJJ, Vecht C, Zurcher C, et al.: Intra-CSF administered recombinant adenovirus causes an immune response-mediated toxicity. Gene Ther 2000, 7: 1401-1409. 10.1038\/sj.gt.3301250","journal-title":"Gene Ther"},{"key":"1278_CR28","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/jgm.1110","volume":"9","author":"M Horst","year":"2007","unstructured":"Horst M, Brouwer E, Verwijnen S, Rodijk M, De JM, Hoeben R, et al.: Targeting malignant gliomas with a glial fibrillary acidic protein (GFAP)-selective oncolytic adenovirus. J Gene Med 2007, 9: 1071-1079. 10.1002\/jgm.1110","journal-title":"J Gene Med"},{"key":"1278_CR29","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S1525-0016(03)00100-X","volume":"7","author":"P Sillevis Smitt","year":"2003","unstructured":"Sillevis Smitt P, Driesse M, Wolbers J, Kros M, Avezaat C: Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. Mol Ther 2003, 7: 851-858. 10.1016\/S1525-0016(03)00100-X","journal-title":"Mol Ther"},{"key":"1278_CR30","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/00006123-199708000-00023","volume":"41","author":"AJ Vincent","year":"1997","unstructured":"Vincent AJ, Esandi MC, Avezaat CJ, Vecht CJ, Sillevis Smitt P, van Bekkum DW, et al.: Preclinical testing of recombinant adenoviral herpes simplex virus-thymidine kinase gene therapy for central nervous system malignancies. Neurosurgery 1997, 41: 451-452. 10.1097\/00006123-199708000-00023","journal-title":"Neurosurgery"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1743-422X-8-162.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T13:34:22Z","timestamp":1630503262000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/1743-422X-8-162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,11]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["1278"],"URL":"https:\/\/doi.org\/10.1186\/1743-422x-8-162","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,11]]},"assertion":[{"value":"5 November 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"162"}}